Cocaine and Sleep: Early Abstinence
|
|
|
- Garey Wright
- 10 years ago
- Views:
Transcription
1 Mini-Review NIDA Special Issue on Frontiers in Addiction Research TheScientificWorldJOURNAL (2007) 7(S2), ISSN X; DOI /tsw Cocaine and Sleep: Early Abstinence Peter T. Morgan* and Robert T. Malison Department of Psychiatry, Yale University School of Medicine, New Haven, CT Received June 22, 2007; Revised July 16, 2007; Accepted July 17, 2007; Published November 2, 2007 Compulsive cocaine use is associated with a profound dysregulation of sleep. Perhaps the result of chronic use, a significant deterioration in sleep is apparent over the first 3 weeks of abstinence, with no indication of recovery. Interestingly, the diminished sleep is not accompanied by subjective reports of poor or worsening sleep. Rather, subjective reports actually improve over abstinence, while sleep-related cognitive performance declines. A mechanistic understanding of the apparent difference in objective and subjective measures is currently lacking. Here we review the relevant literature on cocaine use and sleep, and discuss the possible relevance of this sleep disturbance in relationship to the underlying disorder and its treatment. KEYWORDS: cocaine, sleep, insomnia, abstinence, treatment, GABA INTRODUCTION Cocaine dependence is one of many psychiatric illnesses in which sleep problems are common[1]. Emerging evidence suggests that the sleep problems associated with psychiatric illnesses may be more than just symptomatic consequences of the underlying illness[1,2,3,4,5,6,7]. Rather, the sleep disturbances associated with psychiatric illness may be integral to the underlying disease process. If so, appropriate treatment of the sleep disturbance associated with psychiatric illness would be much more than symptom management, as it may be essential to promote recovery fully. For cocaine dependence, this possibility may be particularly important. There is currently no FDAapproved medication for the treatment of cocaine dependence despite many efforts toward this end, so the identification of a novel target for medicinal therapy could have far-reaching implications. Furthermore, recent evidence suggests that the sleep disturbance associated with cocaine dependence persists through at least 3 weeks of abstinence and is associated with sleep-related cognitive deficits[8,9,10,11]. The duration of this disturbance and the apparent functional consequences suggest that the sleep disturbance associated with cocaine dependence may be particularly relevant to relapse to cocaine use. To use the sleep disturbances associated with cocaine dependence as a target for treatment, the characteristics of these disturbances must be well described. This review summarizes the published polysomnographic sleep studies of persons with cocaine dependence, as well as some studies of selfreported sleep and related symptoms in this population. The results from these studies are compared and discussed, and the possible relevance to treatment is considered. *Corresponding author with author. Published by TheScientificWorld; 223
2 POLYSOMNOGRAPHIC (PSG) MEASUREMENT OF SLEEP IN COCAINE DEPENDENCE From 1992 through the present, six published studies[9,10,12,13,14,15] reported polysomnographic sleep measurement in primarily cocaine-dependent (nonopioid dependent), primarily male subjects. Excluding the most recent study, these studies are limited by the small number of subjects studied[10,12,13,16], the lack of controlled cocaine administration[12,14,15], and/or the lack of specificity for cocaine[14,15]. Despite design differences, many findings from these studies are consistent with regard to the effects of cocaine administration and abstinence on sleep (Table 1). The most consistent finding among these studies is the severely disrupted sleep that is most evident after 11 days of abstinence, or more, without evidence of recovery as far as the 3 rd week of abstinence. This disruption is seen as an increase in the time it takes to initiate sleep (increased sleep latency), decreased total time spent asleep, and decreased percentage of time in bed that is spent sleeping (decreased sleep efficiency). Sleep architectural changes are also seen in response to cocaine and cocaine abstinence. On the first night of sleep following laboratory cocaine administration, there is evidence of REM suppression (REM latency relatively increased, REM sleep time decreased, and/or decreased REM pressure)[8,13,16]. A rebound from this suppression is evident within the first few days of abstinence, with decreased REM latency and increased REM sleep time (along with increased total sleep time). In contrast, laboratory cocaine administration seems to increase slow-wave sleep activity on the first night, but as REM sleep increases in the first few days of abstinence, slow-wave sleep decreases[8,9]. As abstinence progresses into the 3 rd week, REM sleep diminishes to very low levels and slow-wave activity is proportionally higher (but overall slow-wave sleep time is still low compared to age-matched normative data). Characteristic examples of how cocaine users polysomnographically sleep change over the course of abstinence are shown in Fig. 1. SELF-REPORTED EFFECTS OF COCAINE AND COCAINE ABSTINENCE ON SLEEP In contrast to PSG sleep, self-reported sleep and related measures, such as daytime sleepiness, energy, concentration, and confusion have shown a much different pattern of response to abstinence. Table 2 summarizes results from five studies that self-report of sleep and related measures in chronic cocaine users across the first 15 days or more of abstinence[9,10,15,17,18]. One study[9] also reported these measures on the nights and mornings after controlled cocaine administration. Although perhaps not as consistent as the polysomnographically sleep data, self-reports of sleep quality and related measures largely improve over the period of abstinence in these studies. The improvement seen in sleep-related measures largely parallels improvements in mood, cocaine craving, and other cocaine withdrawal measures[17]. Most evidence supports monotonic improvements in these measures over abstinence, with some evidence supporting phasic vs. continuous changes. For example, Weddington et al.[17] show a precipitous drop in fatigue over the first 4 days, followed by little change, then another drop at 10 days. It should be noted that Weddington et al.[17] only reported statistical analysis for overall time effects, without comparison of one time point to another, despite several measures showing possible bi- or triphasic response to time abstinent. Morgan et al.[9] found that mental alertness improved significantly at 4 days abstinence relative to earlier in abstinence, but showed no further improvement as abstinence progressed. Other studies (e.g., Coffey et al.[18]) did not measure with sufficient frequency to distinguish phasic vs. continuous changes. Overall sleep quality self-reported measures, when found to increase, tended to do so continuously over abstinence[9,17], and in Weddington et al.[17] were similar to increases seen in a control group. This raised the possibility that the increases were due to acclimation to a new environment, i.e., the inpatient hospital. However, six of the 12 subjects from Morgan et al.[9] received laboratory cocaine after being in the hospital for 17 days and showed marked drops in self-reported sleep quality on the first 3 days of abstinence after 224
3 TABLE 1 Studies with PSG Sleep Measurement Morgan et al.[9] Pace- Schott et al.[10] Johanson et al.[13] Thompson et al.[14] Gillin et al.[15] Watson et al.[16] Kowatch et al.[12] Number of cocainedependent subjects Laboratory cocaine administration Controlled abstinence Number of days of abstinence observed Comparison to control or normative data REM suppression by cocaine REM rebound in early abstinence REM decline in later abstinence Total sleep time rebound in early abstinence Insomnia-like sleep after 11 days of abstinence or more Slow-wave sleep/slow-wave activity effects Increased daytime sleep latency (Multiple Sleep Latency Test) * 11** 3 3 9*** No No No Up to 14 ~20 3 Up to 17 No No No No No No No reported Limited reported No No * Reflects two sets of seven subjects: one set at 3 10 days abstinent, the other at days abstinent. Of the 14 total subjects, five also (three) or exclusively (two) used amphetamine. ** Includes some subjects with amphetamine dependence, or cocaine and amphetamine dependence *** Data from between three and nine subjects were reported at each of several time points from 2 17 days abstinent. REM data from this study reported in Morgan et al.[8]. Lack of preservation of REM with declining total sleep time. Decreased total sleep time, long sleep latency, poor sleep efficiency, and/or prolonged wake time after sleep onset. 225
4 FIGURE 1. Characteristic examples of polysomnographically sleep at different points along the first 3 weeks of abstinence. On the first night of sleep, 10 h after administration of 12 i.v. doses of 32 mg cocaine/70 kg body mass, REM sleep is suppressed with decreased REM sleep time and relatively increased REM latency. Slow-wave (stages 3 and 4) sleep is prominent in the beginning of the night. Sleep latency is somewhat increased and total sleep time is decreased. At 2.5 days abstinent, a rebound in REM sleep occurs with decreased REM latency and increased REM sleep time. Slow-wave sleep is much less prominent, sleep latency has decreased, and total sleep time has increased. After 2.5 weeks of abstinence, sleep is insomnia-like, with increased sleep latency, low sleep efficiency (% time spent asleep while in bed), and decreased total sleep time. REM sleep time is very short despite a REM latency that is decreased compared to healthy subjects, and the proportion of slow-wave sleep has increased relative to 2.5 days abstinent. Excursions of the hypnograms above the REM line indicate movement or other artifacts. cocaine administration (i.e., after 21 days in the hospital) relative to the few days prior to cocaine administration. This finding leaves open the possibility that the improvement in self-reported sleep with abstinence is related to abstinence itself and not just acclimation to the sleep environment. Overall, there is consistent evidence that there is no decline in self-reported sleep quality as abstinence progresses, and substantial evidence that both perceived sleep quality and related measures, such as fatigue, alertness, and concentration, improve over the first 2 4 weeks of abstinence. THE DISCREPANCY BETWEEN PSG AND SELF-REPORTED SLEEP MEASURES Typical responses to sleep deprivation of the magnitude seen in chronic cocaine users after 2 weeks of abstinence might include sleepiness, fatigue, irritability, poor attentional performance, and increased propensity toward sleep (shortened time to sleep, falling asleep easily during the day)[19,20,21]. Chronic cocaine users, however, are more like insomniacs who have difficulty falling asleep, both at night and during the daytime[13], despite the limited total sleep time. Very much unlike insomniacs, however, chronic cocaine users do not report trouble with their sleep: overall sleep quality and satisfaction with sleep, for example, are comparable to control subjects[17], and as discussed above, either improve or remain stable over abstinence. It has been hypothesized[9] that the discrepancy between PSG and self-reported sleep is due to a dysregulation of the homeostatic sleep drive, the drive toward sleep that builds with increased wakefulness. Such a dysregulation would leave cocaine users with decreased sleepiness (both perception and physiological) despite accumulating deficits secondary to chronic sleep restriction. Alternative explanations considered were that chronic cocaine users simply need less sleep or have more restorative sleep. However, coincident with deteriorating PSG measures of sleep in abstinence are deteriorations of 226
5 TABLE 2 Studies with Self-Reported Sleep and/or Related Measures Morgan et al.[9] Pace-Schott et al.[10] Coffey et al.[18] Gillin et al.[15] Weddington et al.[17] Number of cocainedependent subjects Substantial (>25%) inclusion of women Laboratory cocaine administration * 11** 12 (+10 control subjects) No No No No No No No Controlled abstinence No Number of days of ~20 28 abstinence observed Self-reported sleep quality Improved Unchanged or improved Unchanged Improved (in patients and controls) Self-reported energy or alertness Increased Increased Increased Unchanged Self-reported fatigue or sleepiness Self-reported concentration Self-reported confusion Decreased*** Decreased Decreased Improved Decreased Decreased Decreased * Of the 24 completers (out of 82 enrolled), 12 subjects were dependent on both cocaine and alcohol. ** Includes some subjects with amphetamine dependence, or cocaine and amphetamine dependence. *** Statistical trend. Change with progressive abstinence. Depending on measure used. sleep-related cognitive performance, such as attentional measures[9,11] and sleep-dependent learning[8,9]. These findings strongly suggest that the apparent deficiencies in chronic cocaine users sleep are indeed deficiencies, with functional consequences that could affect treatment retention[22] and propensity to relapse[23,24]. Intriguing in this occult insomnia [9] is the possibility that the cognitive deficits associated with sleep restriction may be separable from the perception of fatigue and sleepiness. GENDER CONSIDERATIONS With little exception, research discussed here has focused largely or entirely on male cocaine users. The one study that had a substantial proportion of female subjects[18] reported no gender differences in selfreported measures of sleep and sleep-related variables across abstinence. However, as yet unpublished data[25] suggest that male and female cocaine users may have markedly different physiologically sleep responses to abstinence. In this study, women did not show a deterioration in sleep with abstinence, did not show sleep-dependent learning deficits, and did not differ from control subjects in total sleep time, sleep efficiency, or sleep-dependent learning at 3 weeks of abstinence (whereas men showed all of the above). As the women in this study were all in the luteal phase at 3 weeks abstinence, it 227
6 is possible that progesterone or its metabolite allopregnanolone could be influencing sleep through GABA A receptor mechanisms. MECHANISMS OF COCAINE EFFECTS ON SLEEP There are only limited data that directly examine the relationship between specific neurotransmitter systems and the effects of chronic cocaine use on sleep. Gillin et al.[15] found that the dopamine D2 receptor agonist lisuride (that also has serotonergic effects) reduced the REM sleep rebound seen in early abstinence from cocaine. This finding suggests that the increase in synaptic dopamine (and perhaps serotonin) due to cocaine could cause the REM inhibition seen with recent use. However, the GABA system is both of critical importance to sleep, is closely linked to dopamine neurotransmission and cocaine dependence (with evidence that GABA receptor agonists modulate aspects of cocaine use behavior), and alterations in the GABA system can have effects similar to those observed during cocaine abstinence[26,27,28,29,30,31,32,33,34,35,36]. Hence, in the absence of more specific data, we hypothesize that the sleep disturbance seen in abstinence from chronic cocaine use is most directly mediated by alterations in GABA signaling that are the result of adaptation to repeated overstimulation of monoaminergic pathways. POSSIBLE TREATMENT IMPLICATIONS The presence of an ongoing and functional disruption of sleep in chronic cocaine users raises the possibility of treatment of cocaine dependence through a sleep-affecting medication. The characteristic effects of cocaine and cocaine abstinence on sleep architecture should be considered in such treatment considerations. The low levels of REM sleep present in abstinence beyond the initial rebound caution against a REM suppressing agent. Although cocaine itself is effective in temporarily reversing the sleep time and REM deficits that develop in the 2 nd week of abstinence, it is only in the withdrawal from cocaine (after at least 24 h of abstinence) that this temporary reversal is achieved. Hence, from the standpoint of treating the sleep deficit of cocaine dependence, long-acting dopamine agonists (replacement therapy) given alone should not be effective, but perhaps worsen or at least sustain the problem. This may be particularly true for the typical binge user of cocaine, where periods of heavy use are followed by several days of nonuse. In addressing the shortened total sleep time, an agent that promotes slow-wave sleep and perhaps aids cognitive recovery from sleep restriction (e.g., tiagabine[37]) may be more helpful than an agent that extends sleep only through promoting stage 2 sleep (e.g., benzodiazepines). ably, promising candidate pharmacotherapies for cocaine addiction either have effects on sleep or daytime wakefulness/cognition: gamma-vinyl GABA[35], tiagabine[33,34], and topiramate[38] may alter sleep through GABAergic mechanisms; modafinil[39] improves vigilance and appears to alter the homeostatic sleep/wake drive[40]. An agent not yet tested in cocaine dependence, gaboxadol (a modulator of largely extrasynaptic GABA A receptors), is particularly interesting as it both promotes slow-wave sleep and lengthens total sleep time[41,42]. The intriguing possibility that lutealphase women are protected against the observed sleep disruption suggests that a natural sex hormone (e.g., progesterone) could play a role in treating this aspect of cocaine abstinence ACKNOWLEDGMENTS This work was supported by NIH grants K12RR17594 (PTM), R01 DA15857 and K02 DA00397 (RTM), the Yale General Clinical Research Center (funded by NIH/NCRR/GCRC Program Grant M01- RR00125), and the Connecticut Department of Mental Health and Addiction Services (DMHAS). 228
7 REFERENCES 1. Breslau, N. et al. (1996) Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol. Psychiatry 39(6), Fava, M. et al. (2006) Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol. Psychiatry 59(11), Le Bon, O. (2005) Contribution of sleep research to the development of new antidepressants. Dialogues Clin. Neurosci. 7(4), Monnelly, E.P. et al. (2004) Quetiapine for treatment of alcohol dependence. J. Clin. Psychopharmacol. 24(5), Brower, K.J., Aldrich, M.S., and Hall, J.M. (1998) Polysomnographic and subjective sleep predictors of alcoholic relapse. Alcohol Clin. Exp. Res. 22(8), Brower, K.J. (2003) Insomnia, alcoholism and relapse. Sleep Med. Rev. 7(6), Landolt, H.P. and Gillin, J.C. (2001) Sleep abnormalities during abstinence in alcohol-dependent patients. Aetiology and management. CNS Drugs 15(5), Morgan, P.T. et al. (2007) Cocaine, Sleep Architecture, and Visual Learning, in revision. 9. Morgan, P.T. et al. (2006) Sleep, sleep-dependent procedural learning and vigilance in chronic cocaine users: evidence for occult insomnia. Drug Alcohol Depend. 82(3), Pace-Schott, E.F. et al. (2005) Sleep quality deteriorates over a binge--abstinence cycle in chronic smoked cocaine users. Psychopharmacology (Berl.) 179(4), Pace-Schott, E.F. et al. (2005) Cognitive performance by humans during a smoked cocaine binge-abstinence cycle. Am. J. Drug Alcohol Abuse 31, Kowatch, R.A. et al. (1992) Electroencephalographic sleep and mood during cocaine withdrawal. J. Addict. Dis. 11(4), Johanson, C.E. et al. (1999) The effects of cocaine on mood and sleep in cocaine-dependent males. Exp. Clin. Psychopharmacol. 7(4), Thompson, P.M. et al. (1995) Polygraphic sleep measures differentiate alcoholics and stimulant abusers during shortterm abstinence. Biol. Psychiatry 38(12), Gillin, J.C. et al. (1994) The effects of lisuride on mood and sleep during acute withdrawal in stimulant abusers: a preliminary report. Biol. Psychiatry 35(11), Watson, R. et al. (1992) Cocaine use and withdrawal: the effect on sleep and mood. Am. J. Drug Alcohol Abuse 18(1), Weddington, W.W. et al. (1990) Changes in mood, craving, and sleep during short-term abstinence reported by male cocaine addicts. A controlled, residential study. Arch. Gen. Psychiatry 47(9), Coffey, S.F. et al. (2000) Acute and protracted cocaine abstinence in an outpatient population: a prospective study of mood, sleep and withdrawal symptoms. Drug Alcohol Depend. 59(3), Durmer, J.S. and Dinges, D.F. (2005) Neurocognitive consequences of sleep deprivation. Semin. Neurol. 25(1), Jewett, M.E. et al. (1999) Dose-response relationship between sleep duration and human psychomotor vigilance and subjective alertness. Sleep 22(2), Van Dongen, H.P. et al. (2003) The cumulative cost of additional wakefulness: dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. Sleep 26(2), Aharonovich, E., Nunes, E., and Hasin, D. (2003) Cognitive impairment, retention and abstinence among cocaine abusers in cognitive-behavioral treatment. Drug Alcohol Depend. 71(2), Teichner, G., Horner, M.D., and Harvey, R.T. (2001) Neuropsychological predictors of the attainment of treatment objectives in substance abuse patients. Int. J. Neurosci. 106(3 4), Teichner, G. et al. (2002) Substance abuse treatment outcomes for cognitively impaired and intact outpatients. Addict. Behav. 27(5), Morgan, P.T. et al. (2007) Gender Differences in Sleep and Sleep-Dependent Learning in Abstinent Cocaine Users. Presentation. College on Problems of Drug Dependence (CPDD) Annual Meeting, Quebec City, June Centonze, D. et al. (2002) Cocaine and amphetamine depress striatal GABAergic synaptic transmission through D2 dopamine receptors. Neuropsychopharmacology 26(2), Doherty, M. and Gratton, A. (2007) Differential involvement of ventral tegmental GABA(A) and GABA(B) receptors in the regulation of the nucleus accumbens dopamine response to stress. Brain Res. 1150, Barrett, A.C. et al. (2005) Effect of GABA agonists and GABA-A receptor modulators on cocaine- and foodmaintained responding and cocaine discrimination in rats. J. Pharmacol. Exp. Ther. 315(2), Haney, M., Hart, C.L., and Foltin, R.W. (2006) Effects of baclofen on cocaine self-administration: opioid- and nonopioid-dependent volunteers. Neuropsychopharmacology 31(8), Roberts, D.C. (2005) Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction. Physiol. Behav. 86(1 2), Weerts, E.M., Froestl, W., and Griffiths, R.R. (2005) Effects of GABAergic modulators on food and cocaine self- 229
8 administration in baboons. Drug Alcohol Depend. 80(3), Johnson, B.A. (2005) Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function. CNS Drugs 19(10), Gonzalez, G. et al. (2003) Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction 98(11), Gonzalez, G. et al. (2007) Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug Alcohol Depend. 87(1), Brodie, J.D., Figueroa, E., and Dewey, S.L. (2003) Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA. Synapse 50(3), Winhusen, T.M. et al. (2005) A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction 100(Suppl 1), Walsh, J.K. et al. (2006) Tiagabine is associated with sustained attention during sleep restriction: evidence for the value of slow-wave sleep enhancement? Sleep 29(4), Kampman, K.M. et al. (2004) A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. 75(3), Dackis, C.A. et al. (2005) A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30(1), Chapotot, F. et al. (2003) Distinctive effects of modafinil and d-amphetamine on the homeostatic and circadian modulation of the human waking EEG. Psychopharmacology (Berl.) 166(2), Winsky-Sommerer, R. et al. (2007) The EEG effects of THIP (Gaboxadol) on sleep and waking are mediated by the GABA(A)delta-subunit-containing receptors. Eur. J. Neurosci. 25(6), Orser, B.A. (2006) Extrasynaptic GABAA receptors are critical targets for sedative-hypnotic drugs. J. Clin. Sleep Med. 2(2), S This article should be cited as follows: Morgan, P.T. and Malison, R.T. (2007) Cocaine and sleep: early abstinence. TheScientificWorldJOURNAL 7(S2), DOI /tsw
9 MEDIATORS of INFLAMMATION The Scientific World Journal Gastroenterology Research and Practice Diabetes Research International Endocrinology Immunology Research Disease Markers Submit your manuscripts at BioMed Research International PPAR Research Obesity Ophthalmology Evidence-Based Complementary and Alternative Medicine Stem Cells International Oncology Parkinson s Disease Computational and Mathematical Methods in Medicine AIDS Behavioural Neurology Research and Treatment Oxidative Medicine and Cellular Longevity
Supplements in Psychiatry: N-Acetylcysteine, Omega-3 Fatty Acids & Melatonin. March 19, 2004 David A. Graeber, MD UNM Department of Psychiatry
Supplements in Psychiatry: N-Acetylcysteine, Omega-3 Fatty Acids & Melatonin March 19, 2004 David A. Graeber, MD UNM Department of Psychiatry 1 N-Acetylcysteine = NAC NAC modulates Neurotransmitters: 1.
Alcohol Overuse and Abuse
Alcohol Overuse and Abuse ACLI Medical Section CME Meeting February 23, 2015 Daniel Z. Lieberman, MD Professor and Vice Chair Department of Psychiatry George Washington University Alcohol OVERVIEW Definitions
Treatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call the
Co-Occurring Substance Use and Mental Health Disorders. Joy Chudzynski, PsyD UCLA Integrated Substance Abuse Programs
Co-Occurring Substance Use and Mental Health Disorders Joy Chudzynski, PsyD UCLA Integrated Substance Abuse Programs Introduction Overview of the evolving field of Co-Occurring Disorders Addiction and
Sleep Medicine and Psychiatry. Roobal Sekhon, D.O.
Sleep Medicine and Psychiatry Roobal Sekhon, D.O. Common Diagnoses Mood Disorders: Depression Bipolar Disorder Anxiety Disorders PTSD and other traumatic disorders Schizophrenia Depression and Sleep: Overview
Medical marijuana for pain and anxiety: A primer for methadone physicians. Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015
Medical marijuana for pain and anxiety: A primer for methadone physicians Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015 Conflict of interest statement No conflict of interest to
Treatment of Prescription Opioid Dependence
Treatment of Prescription Opioid Dependence Roger D. Weiss, MD Chief, Division of Alcohol and Drug Abuse McLean Hospital, Belmont, MA Professor of Psychiatry, Harvard Medical School, Boston, MA Prescription
Systematic Review of Treatment for Alcohol Dependence
Systematic Review of Treatment for Alcohol Dependence ALCOHOL ARCUATE NUCLEUS in Hypothalamus, pituitary Beta-endorphin Dynorphin Kappa receptor Nucleus Enkephalins accumbens Delta receptor (+) Mu receptor
DrugFacts: Treatment Approaches for Drug Addiction
DrugFacts: Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please
12 Steps to Changing Neuropathways. Julie Denton
12 Steps to Changing Neuropathways Julie Denton Review the neurobiology of the brain Understand the basics of neurological damage to the brain from addiction Understand how medications and psychotherapy
Drugs, The Brain, and Behavior
Drugs, The Brain, and Behavior John Nyby Department of Biological Sciences Lehigh University What is a drug? Difficult to define Know it when you see it Neuroactive vs Non-Neuroactive drugs Two major categories
SLEEP DISTURBANCE AND PSYCHIATRIC DISORDERS
E-Resource December, 2013 SLEEP DISTURBANCE AND PSYCHIATRIC DISORDERS Between 10-18% of adults in the general population and up to 50% of adults in the primary care setting have difficulty sleeping. Sleep
SC 215 FIGHTING DRUG ADDICTION WITH DRUGS. John Bush April 15, 2013
SC 215 FIGHTING DRUG ADDICTION WITH DRUGS John Bush April 15, 2013 ADDICTION A persistent, compulsive dependence on a behavior or substance Behavioral Compulsive shopping --Compulsive eating Compulsive
Sponsored by: 2013 NAMI Maryland Conference Baltimore, Maryland; Friday, October 18 th, 2013
Integrated System of Care Universal Dual Diagnosis Capabilities Principles of Empathy and Hope Motivational Interviewing Approach Stages of Change Model Design Solution Focused Strength Based Skill Building
Addiction Neurobiology
Addiction Neurobiology Stephen Jurd University of Sydney Australia Richard W is sick Apology The site of pathology IF Addiction has a neurobiological basis THEN we should be able to: Define addiction AND
Tolerance and Dependence
Tolerance and Dependence Drug Tolerance is a decrease in the effect of a drug as a consequence of repeated exposure. Change over repeated exposures. Different effects may show different tolerance. Tolerance
Source: National Institute on Alcohol Abuse and Alcoholism. Bethesda, Md: NIAAA; 2004. NIH Publication No. 04-3769.
Diagnosis and Treatment of Alcohol Dependence Lon R. Hays, MD, MBA Professor and Chairman Department of Psychiatry University of Kentucky Medical Center Defining the Standard Drink A standard drink = 14
WHAT HAPPENS TO OUR BRAIN?
WORK DYNAMIC The final result of this session is the formulation of the questions that, within the activity of the Let s talk about drugs programme of the la Caixa Welfare Project, you will ask Dr. Rafael
Naltrexone and Alcoholism Treatment Test
Naltrexone and Alcoholism Treatment Test Following your reading of the course material found in TIP No. 28. Please read the following statements and indicate the correct answer on the answer sheet. A score
Headache and Sleep Disorders 屏 東 基 督 教 醫 院 沈 秀 祝
Headache and Sleep Disorders 屏 東 基 督 教 醫 院 沈 秀 祝 Sleep Sleeping later Sleep deprivation Excessive Sleep Sleep Migraine Physiology of sleep Headache Clinical, Anatomical, and Physiologic Relationship Between
AMPHETAMINE AND COCAINE MECHANISMS AND HAZARDS
AMPHETAMINE AND COCAINE MECHANISMS AND HAZARDS BARRY J. EVERITT Department of Experimental Psychology, University of Cambridge Stimulant drugs, such as cocaine and amphetamine, interact directly with dopamine
Identification, treatment and support for individuals with Alcohol & Drug Addiction in the Community
Identification, treatment and support for individuals with Alcohol & Drug Addiction in the Community Dr David Jackson Clinic Medical Officer The Hobart Clinic Association Drugs In tonight s context, drugs
COUNTY OF LOS ANGELES - DEPARTMENT OF MENTAL HEALTH OFFICE OF THE MEDICAL DIRECTOR. 3.4 PARAMETERS FOR THE USE OF ANXIOLYTIC MEDICATIONS October 2014
COUNTY OF LOS ANGELES - DEPARTMENT OF MENTAL HEALTH OFFICE OF THE MEDICAL DIRECTOR 3.4 PARAMETERS FOR THE USE OF ANXIOLYTIC MEDICATIONS October 2014 I. GENERAL CONSIDERATIONS A. Definition: Anxiolytic
Brain Damage & Recovery: The Resilience of the Brain, Addiction Impact & Therapeutic Repair. Michael Fishman, MD Director of Young Adult Program
Brain Damage & Recovery: The Resilience of the Brain, Addiction Impact & Therapeutic Repair Michael Fishman, MD Director of Young Adult Program How Addiction Takes Hold Large & rapid upsurges in dopamine
Treatment of Methamphetamine Dependence: A brief overview
Treatment of Methamphetamine Dependence: A brief overview Richard A. Rawson, Ph.D Adjunct Associate Professor Semel Institute for Neuroscience and Human Behavior David Geffen School of Medicine University
Causes of Alcohol Abuse and Alcoholism: Biological/Biochemical Perspectives
Causes of Alcohol Abuse and Alcoholism: Biological/Biochemical Perspectives Neurobehavioral Aspects of Alcohol Consumption Source: Eighth Special Report to the U.S. Congress on Alcohol and Health Secretary
See also www.thiswayup.org.au/clinic for an online treatment course.
Depression What is depression? Depression is one of the common human emotional states. It is common to experience feelings of sadness and tiredness in response to life events, such as losses or disappointments.
Source: National Institute on Alcohol Abuse and Alcoholism. Bethesda, Md: NIAAA; 2004. NIH Publication No. 04-3769.
Diagnosis and Treatment of Alcohol Dependence Lon R. Hays, MD, MBA Professor and Chairman an Department of Psychiatry University of Kentucky Medical Center Defining the Standard Drink A standard drink
The Results of a Pilot of Vivitrol: A Medication Assisted Treatment for Alcohol and Opioid Addiction
The Results of a Pilot of Vivitrol: A Medication Assisted Treatment for Alcohol and Opioid Addiction James H. Barger, MD SAPC Medical Director and Science Officer Desiree A. Crevecoeur-MacPhail, Ph.D.
placebo-controlledcontrolled double-blind, blind,
Clinical Potential of Minocycline for Depression with Psychotic Features Tsuyoshi Miyaoka Department of Psychiatry Shimane University School of Medicine Minocycline 1. Second-generation tetracycline which
THE DEPRESSION RESEARCH CLINIC Department of Psychiatry and Behavioral Sciences Stanford University, School of Medicine
THE DEPRESSION RESEARCH CLINIC Department of Psychiatry and Behavioral Sciences Stanford University, School of Medicine Volume 1, Issue 1 August 2007 The Depression Research Clinic at Stanford University
The Brain, Behavior, and Addiction. Objectives. Advances in science have revolutionized our fundamental views of drug abuse and addiction.
The Brain, Behavior, and Addiction Flo Hilliard University of Wisconsin-Madison Division of Continuing Studies Objectives Progress of science in addiction studies Why it is a brain disease Changing our
ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines - 2015
The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the least
Sleep Difficulties. Insomnia. By Thomas Freedom, MD and Johan Samanta, MD
Sleep Difficulties By Thomas Freedom, MD and Johan Samanta, MD For most people, night is a time of rest and renewal; however, for many people with Parkinson s disease nighttime is a struggle to get the
The latest in addiction medicine: What every nurse needs to know
CNA Webinar Series: Progress in Practice The latest in addiction medicine: What every nurse needs to know Monica Gregory Nurse Practitioner, Crosstown Clinic December 4, 2014 Canadian Nurses Association,
Alcohol Withdrawal Syndrome & CIWA Assessment
Alcohol Withdrawal Syndrome & CIWA Assessment Alcohol Withdrawal Syndrome is a set of symptoms that can occur when an individual reduces or stops alcoholic consumption after long periods of use. Prolonged
PRESCRIPTION DRUG ABUSE prevention
PRESCRIPTION DRUG ABUSE prevention Understanding Drug Addiction Many people do not understand how someone could abuse drugs even when their life seems to be falling apart. It is often assumed that those
Frequently Asked Questions About Prescription Opioids
Mental Health Consequences of Prescription Drug Addictions Opioids, Hypnotics and Benzodiazepines Learning Objectives 1. To review epidemiological data on prescription drug use disorders Ayal Schaffer,
Produced and Published by The Cabin Chiang Mai, Alcohol and Drug Rehab Centre. Copyright 2013. and How is it Treated?
and How is it Treated? 1 About this book This E-book has been produced as a guide to help explain some of the fundamental things you need to understand about addiction and its treatment, starting with
Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial
Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial Barbara J. Mason, Ph.D. Professor, Committee on the Neurobiology of Addictive Disorders Director, Laboratory of Clinical Psychopharmacology
Assessment and Diagnosis of DSM-5 Substance-Related Disorders
Assessment and Diagnosis of DSM-5 Substance-Related Disorders Jason H. King, PhD (listed on p. 914 of DSM-5 as a Collaborative Investigator) [email protected] or 801-404-8733 www.lecutah.com D I S C L
Recognizing and Treating Depression in Children and Adolescents.
Recognizing and Treating Depression in Children and Adolescents. KAREN KANDO, MD Division of Child and Adolescent Psychiatry Center for Neuroscience and Behavioral Medicine Phoenix Children s Hospital
Developing Medications to Treat Addiction: Implications for Policy and Practice. Nora D. Volkow, M.D. Director National Institute on Drug Abuse
Developing Medications to Treat Addiction: Implications for Policy and Practice Nora D. Volkow, M.D. Director National Institute on Drug Abuse Medications Currently Available For Nicotine Addiction Nicotine
Targeting brain inflammation to treat methamphetamine addiction
Targeting brain inflammation to treat methamphetamine addiction Keith Heinzerling MD MPH UCLA Center for Behavioral and Addiction Medicine UCLA Department of Family Medicine October 23, 2014 Advancing
SUBSTANCE ABUSE & DEPRESSION: WHAT YOU SHOULD KNOW
SUBSTANCE ABUSE & DEPRESSION: WHAT YOU SHOULD KNOW TABLE OF CONTENTS What is Depression? 4 Symptoms of Depression 6 Substance Abuse as a Coping Mechanism 8 Which Occurs First? 10 Substance Abuse and the
Addictions: Why Don t They Just Quit?
Counseling Center of New Smyrna Beach 265 N. Causeway New Smyrna Beach FL 32169 Ph: 386-423-9161 Fax: 386-423-3094 Addictions: Why Don t They Just Quit? By Shane Porter One of the most frustrating issues
Medications Used in the Treatment of Addiction Developed by Randall Webber, MPH. Alcohol Withdrawal
Medications Used in the Treatment of Addiction Developed by Randall Webber, MPH Alcohol Withdrawal MEDICATION Long/intermediateacting benzodiazepines (e.g., chlordiazepoxide/ Librium, diazepam/valium)
Substance Addiction. A Chronic Brain Disease
Substance Addiction A Chronic Brain Disease What you will Learn Addiction is a Brain Disease Understand the Structure and Pathways Associated with changes in the brain. Addiction is a Chronic Condition
Conjoint Professor Brian Draper
Chronic Serious Mental Illness and Dementia Optimising Quality Care Psychiatry Conjoint Professor Brian Draper Academic Dept. for Old Age Psychiatry, Prince of Wales Hospital, Randwick Cognitive Course
MINISTERIO DE SALUD PUBLICA DIRECCION PROVINCIAL DE SALUD DEL GUAYAS HOSPITAL DE INFECTOLOGIA DR. JOSE DANIEL RODRIGUEZ MARIDUEÑA Guayaquil - Ecuador
EVALUATION OF THE EFFECTIVENESS OF THE PRODUCT BABUNA IN THE TREATMENT OF INSOMNIA, IN PATIENTS OF THE MALE WING OF THE ECUADORIAN HEALTH MINISTRY S HOSPITAL OF INFECTIOUS DISEASE PILLASAGUA Diana, ANDINO
Managing Chronic Pain in Adults with Substance Use Disorders
Question from chapter 1 Managing Chronic Pain in Adults with Substance Use Disorders 1) What is the percent of chronic pain patients who may have addictive disorders? a) 12% b) 22% c) 32% d) 42% 2) Which
Office-based Treatment of Opioid Dependence with Buprenorphine
Office-based Treatment of Opioid Dependence with Buprenorphine David A. Fiellin, M.D Professor of Medicine, Investigative Medicine and Public Health Yale University School of Medicine Dr. Fiellin s Disclosures
What is Addiction and How Do We Treat It? Roger D. Weiss, M.D. Professor of Psychiatry, Harvard Medical School Clinical Director, Alcohol and Drug
What is Addiction and How Do We Treat It? Roger D. Weiss, M.D. Professor of Psychiatry, Harvard Medical School Clinical Director, Alcohol and Drug Abuse Treatment Program, McLean Hospital, Belmont, MA
Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone )
Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone ) Elinore F. McCance-Katz, M.D., Ph.D. Professor and Chair, Addiction Psychiatry Virginia Commonwealth University Neurobiology of Opiate
Research Article Predictors of Dropout from Inpatient Opioid Detoxification with Buprenorphine: A Chart Review
Addiction, Article ID 965267, 5 pages http://dx.doi.org/10.1155/2014/965267 Research Article Predictors of Dropout from Inpatient Opioid Detoxification with Buprenorphine: A Chart Review Anders Hakansson
SLEEP DIFFICULTIES AND PARKINSON S DISEASE Julie H. Carter, R.N., M.S., A.N.P.
SLEEP DIFFICULTIES AND PARKINSON S DISEASE Julie H. Carter, R.N., M.S., A.N.P. Problems with sleep are common in Parkinson s disease. They can sometimes interfere with quality of life. It is helpful to
How To Treat An Addict
Steven J. Lee, MD Assistant Clinical Professor of Psychiatry Columbia University New York, New York 10011 Vila Serena Bahia, BA Brazil October 1, 2010 Overview Mechanism of Action Psychosocial Treatments
Why Meditation is successful in Substance abuse treatment. Mediation paired with substance abuse treatment has been around since 1982 when the
Stone Amber Stone Mathew Arndt HLTH-1240 26 June 2014 Why Meditation is successful in Substance abuse treatment. Mediation paired with substance abuse treatment has been around since 1982 when the Betty
Medical Information to Support the Decisions of TUECs INTRINSIC SLEEP DISORDERS
Introduction Excessive daytime sleepiness (EDS) is a common complaint. Causes of EDS are numerous and include: o Intrinsic sleep disorders (e.g. narcolepsy, obstructive sleep apnoea/hypopnea syndrome (OSAHS)
Philip Moore DO, Toxicology Fellow, PinnacleHealth Toxicology Center Joanne Konick-McMahan RN MSRN, Staff RN, PinnacleHealth
Philip Moore DO, Toxicology Fellow, PinnacleHealth Toxicology Center Joanne Konick-McMahan RN MSRN, Staff RN, PinnacleHealth I. II. Background A. AWS can occur in anyone who consumes alcohol B. Risk correlates
SLEEP AND PARKINSON S DISEASE
A Practical Guide on SLEEP AND PARKINSON S DISEASE MICHAELJFOX.ORG Introduction Many people with Parkinson s disease (PD) have trouble falling asleep or staying asleep at night. Some sleep problems are
TITLE: Acupuncture for Management of Addictions Withdrawal: Clinical Effectiveness
TITLE: Acupuncture for Management of Addictions Withdrawal: Clinical Effectiveness DATE: 09 October 2008 RESEARCH QUESTION: What is the clinical effectiveness of auricular acupuncture in the management
NEUROPHARMACOLOGY AND ADDICTION CHRISTOPHER M. JONES, PHARMD, MPH
NEUROPHARMACOLOGY AND ADDICTION CHRISTOPHER M. JONES, PHARMD, MPH Disclosures This presentation does not represent the views of the US Public Health Service or the US Food and Drug Administration The majority
How To Understand The Effects Of Drugs On The Brain
DRUGS AND THE BRAIN Most of the psychological and behavioural effects of psychoactive drugs is due the interaction they have with the nerve cells in the CNS (which includes the brain and peripheral nervous
What is Addiction? DSM-IV-TR Substance Abuse Criteria
Module 2: Understanding Addiction, Recovery, and Recovery Oriented Systems of Care This module reviews the processes involved in addiction and what is involved in recovering an addiction free lifestyle.
Addiction is a Brain Disease
Addiction is a Brain Disease By ALAN I. LESHNER, MD A core concept evolving with scientific advances over the past decade is that drug addiction is a brain disease that develops over time as a result of
American Society of Addiction Medicine
American Society of Addiction Medicine Public Policy Statement on Parity in Benefit Coverage: A Joint Statement by ASAM and AMBHA The American Managed Behavioral Healthcare Association (AMBHA) and the
Update and Review of Medication Assisted Treatments
Update and Review of Medication Assisted Treatments for Opiate and Alcohol Use Disorders Richard N. Whitney, MD Medical Director Addiction Services Shepherd Hill Newark, Ohio Medication Assisted Treatment
Depression in Older Persons
Depression in Older Persons How common is depression in later life? Depression affects more than 6.5 million of the 35 million Americans aged 65 or older. Most people in this stage of life with depression
Scientific Facts on. Psychoactive Drugs. Tobacco, Alcohol, and Illicit Substances
page 1/5 Scientific Facts on Psychoactive Drugs Tobacco, Alcohol, and Illicit Substances Source document: WHO (2004) Summary & Details: GreenFacts Context - Psychoactive drugs such as tobacco, alcohol,
Using Drugs to Treat Drug Addiction How it works and why it makes sense
Using Drugs to Treat Drug Addiction How it works and why it makes sense Jeff Baxter, MD University of Massachusetts Medical School May 17, 2011 Objectives Biological basis of addiction Is addiction a chronic
Understanding Addiction: The Intersection of Biology and Psychology
Understanding Addiction: The Intersection of Biology and Psychology Robert Heimer, Ph.D. Yale University School of Public Health Center for Interdisciplinary Research on AIDS New Haven, CT, USA November
Advanced Treatment for Opioid & Alcohol Dependence. John Larson, M.D. Corporate Medical Director Gateway Foundation
Advanced Treatment for Opioid & Alcohol Dependence John Larson, M.D. Corporate Medical Director Gateway Foundation Background 41 years practicing psychiatry Last 15 in addiction medicine I ve watched a
Addiction and the Brain's Pleasure Pathway: Beyond Willpower
Addiction and the Brain's Pleasure Pathway: Beyond Willpower The human brain is an extraordinarily complex and fine-tuned communications network containing billions of specialized cells (neurons) that
Treatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call 1-800-662-HELP(4357)
Ch 7 Altered States of Consciousness
Ch 7 Altered States of Consciousness Consciousness a state of awareness Altered State of Consciousness involves a change in mental processes in which one is not completely aware Sleep is a state of altered
DSM-IV Alcohol Dependence. Alcohol and Drug Abuse. Screening for Alcohol Risk. DSM-IV Alcohol Abuse
DSM-IV Alcohol Dependence Alcohol and Drug Abuse David Gilder, MD Division of Mental Health Scripps Clinic Alcohol Research Center The Scripps Research Institute 1.5.11 Three or more criteria, same 12
Update on Buprenorphine: Induction and Ongoing Care
Update on Buprenorphine: Induction and Ongoing Care Elizabeth F. Howell, M.D., DFAPA, FASAM Department of Psychiatry, University of Utah School of Medicine North Carolina Addiction Medicine Conference
Schizoaffective Disorder
FACT SHEET 10 What Is? Schizoaffective disorder is a psychiatric disorder that affects about 0.5 percent of the population (one person in every two hundred). Similar to schizophrenia, this disorder is
MEDICAL TREATMENT OF DRUG ABUSE
C H A P T E R 7 MEDICAL TREATMENT OF DRUG ABUSE Management principles As with treatment models for chronic diseases, treatment for individuals with substance use disorders occurs in temporal phases that
Seminar/Talk Calendar
Seminar/Talk Calendar Tuesday, February 3rd Dr. John Neumaier, Professor of Psychiatry and Pharmacology, University of Washington DREADDing Addiction Dr. Neumaier s laboratory is studying stress and addiction
Slide 1: Introduction Introduce the purpose of your presentation. Indicate that you will explain how the brain basically works and how and where
Slide 1: Introduction Introduce the purpose of your presentation. Indicate that you will explain how the brain basically works and how and where drugs such as heroin and cocaine work in the brain. Tell
LESSON 5.7 WORKBOOK Is addiction a chronic disease?
DEFINITIONS OF TERMS Addiction is a disease idea that states drug addiction is no different from other chronic diseases, like diabetes and heart disease, and thus needs to be treated as a distinct medical
Treatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy
Category: Heroin Title: Methadone Maintenance vs 180-Day psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial Authors: Karen L. Sees, DO, Kevin L. Delucchi,
Patients are still addicted Buprenorphine is simply a substitute for heroin or
BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals Module VI: Myths About the Use of Medication in Recovery Patients are still addicted Buprenorphine is simply a substitute
These changes are prominent in individuals with severe disorders, but also occur at the mild or moderate level.
Substance-Related Disorders DSM-V Many people use words like alcoholism, drug dependence and addiction as general descriptive terms without a clear understanding of their meaning. What does it really mean
1. According to recent US national estimates, which of the following substances is associated
1 Chapter 36. Substance-Related, Self-Assessment Questions 1. According to recent US national estimates, which of the following substances is associated with the highest incidence of new drug initiates
Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents
These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder,
FRN Research Report March 2011: Correlation between Patient Relapse and Mental Illness Post-Treatment
FRN Research Report March 2011: Correlation between Patient Relapse and Mental Illness Post-Treatment Background Studies show that more than 50% of patients who have been diagnosed with substance abuse
California Society of Addiction Medicine (CSAM) Consumer Q&As
C o n s u m e r Q & A 1 California Society of Addiction Medicine (CSAM) Consumer Q&As Q: Is addiction a disease? A: Addiction is a chronic disorder, like heart disease or diabetes. A chronic disorder is
